Thus, tumor immune surveillance and relapse-free survival observed in the patient after vaccination might be mediated by DNAJB1-PRKACA-specific CD4+ T cells alone53, or accompanied by undetected CD8+ T cells recognizing other tumor antigens that were induced by the CD4+ T cells via epitope spreading54. This evidence concerns the gene CD8A and neoplasm.